您搜索了: policy limit and limits of liability (丹麦语 - 荷兰语)

3.2.3 finally, the scope and the duration of liability differ.
3.2.3 tenslotte verschillen reikwijdte en duur van de aansprakelijkheid.

uln = upper limit of normal (øvre normale grænse).
* elke patiënt kan in één of meer groepen vertegenwoordigd zijn * * vergelijkbaar met toxiciteitsgraad 3 in overeenstemming met de aangepaste who criteria uln = upper limit of normal (bovengrens van de normaal waarde)

uln = upper limit of normal (Øvre grænse for normalt område)
uln = upper limit of normal (bovengrens van normaal)

and check whether limits and reservations set by each target2 participant in relation to each relevant pm account are respected .
and check whether limits and reservations set by each target2 participant in relation to each relevant pm account are respected .

moreover , no limits and reservations shall be taken into account .
moreover , no limits and reservations shall be taken into account .

the making of a compensation offer shall not constitute an admission of liability by the ecb or any other cb in respect of a technical malfunction of target2 .
the making of a compensation offer shall not constitute an admission of liability by the ecb or any other cb in respect of a technical malfunction of target2 .

and ( ii ) check whether limits and reservations set by each target2 participant in relation to each relevant pm account are respected .
and ( ii ) check whether limits and reservations set by each target2 participant in relation to each relevant pm account are respected .

sammenlignelig med 3. grads toksicitet i henhold til uln = upper limit of normal (øvre normale grænse).
* elke patiënt kan in één of meer groepen vertegenwoordigd zijn * * vergelijkbaar met toxiciteitsgraad 3 in overeenstemming met de aangepaste who criteria uln = upper limit of normal (bovengrens van de normaal waarde)

( d ) the making of a compensation offer shall not constitute an admission of liability by the ecb or any other cb in respect of a technical malfunction of target2 .
( d ) the making of a compensation offer shall not constitute an admission of liability by the ecb or any other cb in respect of a technical malfunction of target2 .

payment orders entered into the entry disposition after the start of any of algorithms 1 to 4 may nevertheless be settled immediately in the entry disposition if the positions and limits of the target2 participants » pm accounts concerned are compatible with both the settlement of these payment orders and the settlement of payment orders in the current optimisation procedure .
payment orders entered into the entry disposition after the start of any of algorithms 1 to 4 may nevertheless be settled immediately in the entry disposition if the positions and limits of the target2 participants » pm accounts concerned are compatible with both the settlement of these payment orders and the settlement of payment orders in the current optimisation procedure .

ved kvalitative metoder er detektionsgrænsen (limit of detection — lod) det laveste niveau af analysanden, som kan detekteres med pålideligt resultat, forudsat at antallet af kopier af måltaxonets genom er kendt.
in het geval van kwalitatieve methoden is de aantoonbaarheidsgrens („limit of detection”, lod) het laagste niveau waarbij de analyt op betrouwbare wijze kan worden aangetoond, gegeven het aantal exemplaren van het genoom van het doeltaxon dat voorhanden is.

annex on non- clinical and clinical considerations note for guidance on the non- clinical documentation of medicinal products with well- established use position paper on the limits of genotoxic impurities note for guidance on the need for pre- clinical testing of human pharmaceuticals in juvenile animals note for guidance on environmental risk assessments for pharmaceuticals
annex on non-clinical and clinical considerations note for guidance on the non-clinical documentation of medicinal products with well-established use position paper on the limits of genotoxic impurities note for guidance on the need for pre-clinical testing of human pharmaceuticals in juvenile animals note for guidance on environmental risk assessments for pharmaceuticals

* p- værdi versus adefovirdipivoxil < 0, 05, akomplet respons defineret som hbv- dna- niveauer < 400 kopier/ ml og en forbedring af knodell' s nekroinflammatoriske score på mindst 2 points uden forværring af knodell' s fibrosescore, b forbedring af knodell' s nekroinflammatoriske score på mindst 2 points uden forværring af knodell' s fibrosescore, c median ændring fra baseline hbv dna reflekterer blot forskellen mellem baseline hbv dna og analysens detektionsgrænse (limit of detection - lod), d populationen, som blev brugt til analyse af alat- normalisering, inkluderede kun patienter med alat over uln ved baseline.
* p-waarde versus adefovirdipivoxil < 0,05, a volledige respons gedefinieerd als hbv dna-spiegels < 400 kopieën/ml en verbetering van de knodell-necro-ontstekingsscore met ten minste 2 punten, zonder verslechtering van de knodell- fibrosescore, b verbetering van de knodell-necro-ontstekingsscore met ten minste 2 punten, zonder verslechtering van de knodell-fibrosescore, c mediane verandering ten opzichte van de uitgangswaarde voor hbv dna geeft alleen het verschil weer tussen de hbv dna-uitgangswaarde en de detectielimiet (limit of detection, lod) van de assay, d de populatie die is gebruikt voor de analyse van alt-normalisatie omvatte uitsluitend patiënten met een uitgangswaarde voor alt boven uln.